Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

31 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Necitumumab plus pemetrexed and cisplatin as first-line therapy in patients with stage IV non-squamous non-small-cell lung cancer (INSPIRE): an open-label, randomised, controlled phase 3 study.
Paz-Ares L, Mezger J, Ciuleanu TE, Fischer JR, von Pawel J, Provencio M, Kazarnowicz A, Losonczy G, de Castro G Jr, Szczesna A, Crino L, Reck M, Ramlau R, Ulsperger E, Schumann C, Miziara JE, Lessa ÁE, Dediu M, Bálint B, Depenbrock H, Soldatenkova V, Kurek R, Hirsch FR, Thatcher N, Socinski MA; INSPIRE investigators. Paz-Ares L, et al. Among authors: soldatenkova v. Lancet Oncol. 2015 Mar;16(3):328-37. doi: 10.1016/S1470-2045(15)70046-X. Epub 2015 Feb 18. Lancet Oncol. 2015. PMID: 25701171 Free article. Clinical Trial.
Cisplatin and gemcitabine first-line chemotherapy followed by maintenance gemcitabine or best supportive care in advanced non-small cell lung cancer: a phase III trial.
Brodowicz T, Krzakowski M, Zwitter M, Tzekova V, Ramlau R, Ghilezan N, Ciuleanu T, Cucevic B, Gyurkovits K, Ulsperger E, Jassem J, Grgic M, Saip P, Szilasi M, Wiltschke C, Wagnerova M, Oskina N, Soldatenkova V, Zielinski C, Wenczl M; Central European Cooperative Oncology Group CECOG. Brodowicz T, et al. Among authors: soldatenkova v. Lung Cancer. 2006 May;52(2):155-63. doi: 10.1016/j.lungcan.2006.01.006. Epub 2006 Mar 29. Lung Cancer. 2006. PMID: 16569462 Clinical Trial.
A randomized phase II non-comparative study of pemetrexed‑carboplatin and gemcitabine‑vinorelbine in anthracycline- and taxane-pretreated advanced breast cancer patients.
Amadori D, Carrasco E, Roesel S, Labianca R, Uziely B, Soldatenkova V, Moreau V, Desaiah D, Bauknecht T, Martin M. Amadori D, et al. Among authors: soldatenkova v. Int J Oncol. 2013 May;42(5):1778-85. doi: 10.3892/ijo.2013.1869. Epub 2013 Mar 28. Int J Oncol. 2013. PMID: 23546172 Clinical Trial.
Final results from a Phase II study of pemetrexed and cisplatin with concurrent thoracic radiation after Pem-Cis induction in patients with unresectable locally advanced non-squamous non-small cell lung cancer (NSCLC).
Garrido P, Engel-Riedel W, Serke M, Giraud P, Ricardi U, Vallejo C, Visseren-Grul C, Ameryckx S, Soldatenkova V, Chouaki N, Novello S. Garrido P, et al. Among authors: soldatenkova v. Lung Cancer. 2015 May;88(2):160-6. doi: 10.1016/j.lungcan.2015.02.014. Epub 2015 Feb 23. Lung Cancer. 2015. PMID: 25758556 Free article. Clinical Trial.
A randomized Phase 2 study of pemetrexed in combination with cisplatin or carboplatin as adjuvant chemotherapy in patients with completely resected stage IB or II Non-Small-Cell Lung Cancer.
Schmid-Bindert G, Engel-Riedel W, Reck M, Schuette W, Stöhlmacher J, Fischer JR, Mazières J, Chouaid C, Wolf M, Vinolas N, Soldatenkova V, Ripoche V, Nguyen T, Visseren-Grul C. Schmid-Bindert G, et al. Among authors: soldatenkova v. Lung Cancer. 2015 Dec;90(3):397-404. doi: 10.1016/j.lungcan.2015.11.007. Epub 2015 Nov 7. Lung Cancer. 2015. PMID: 26791798 Clinical Trial.
The Effect of Necitumumab in Combination with Gemcitabine plus Cisplatin on Tolerability and on Quality of Life: Results from the Phase 3 SQUIRE Trial.
Reck M, Socinski MA, Luft A, Szczęsna A, Dediu M, Ramlau R, Losonczy G, Molinier O, Schumann C, Gralla RJ, Bonomi P, Brown J, Soldatenkova V, Chouaki N, Obasaju C, Peterson P, Thatcher N. Reck M, et al. Among authors: soldatenkova v. J Thorac Oncol. 2016 Jun;11(6):808-18. doi: 10.1016/j.jtho.2016.03.002. Epub 2016 Mar 12. J Thorac Oncol. 2016. PMID: 26980471 Free article. Clinical Trial.
Correlation of EGFR-expression with safety and efficacy outcomes in SQUIRE: a randomized, multicenter, open-label, phase III study of gemcitabine-cisplatin plus necitumumab versus gemcitabine-cisplatin alone in the first-line treatment of patients with stage IV squamous non-small-cell lung cancer.
Paz-Ares L, Socinski MA, Shahidi J, Hozak RR, Soldatenkova V, Kurek R, Varella-Garcia M, Thatcher N, Hirsch FR. Paz-Ares L, et al. Among authors: soldatenkova v. Ann Oncol. 2016 Aug;27(8):1573-9. doi: 10.1093/annonc/mdw214. Epub 2016 May 20. Ann Oncol. 2016. PMID: 27207107 Free PMC article. Clinical Trial.
Necitumumab plus Gemcitabine and Cisplatin as First-Line Therapy in Patients with Stage IV EGFR- Expressing Squamous Non-Small-Cell Lung Cancer: German Subgroup Data from an Open-Label, Randomized Controlled Phase 3 Study (SQUIRE).
Reck M, Thomas M, Kropf-Sanchen C, Mezger J, Socinski MA, Depenbrock H, Soldatenkova V, Brown J, Krause T, Thatcher N. Reck M, et al. Among authors: soldatenkova v. Oncol Res Treat. 2016;39(9):539-47. doi: 10.1159/000448085. Epub 2016 Aug 2. Oncol Res Treat. 2016. PMID: 27614872 Free article. Clinical Trial.
Efficacy and Safety of First-Line Necitumumab Plus Gemcitabine and Cisplatin Versus Gemcitabine and Cisplatin in East Asian Patients with Stage IV Squamous Non-small Cell Lung Cancer: A Subgroup Analysis of the Phase 3, Open-Label, Randomized SQUIRE Study.
Park K, Cho EK, Bello M, Ahn MJ, Thongprasert S, Song EK, Soldatenkova V, Depenbrock H, Puri T, Orlando M. Park K, et al. Among authors: soldatenkova v. Cancer Res Treat. 2017 Oct;49(4):937-946. doi: 10.4143/crt.2016.423. Epub 2017 Jan 6. Cancer Res Treat. 2017. PMID: 28111429 Free PMC article. Clinical Trial.
31 results